

# Crystallization of poorly soluble drug in solid dispersion during dissolution



Kateřina Punčochová <sup>a, b</sup>, Josef Beránek <sup>b</sup>, Andrew Ewing <sup>c</sup>, Sergei G. Kazarian <sup>c,\*</sup>, František Štěpánek <sup>a,\*</sup>

**ZENTIVA**  
A SANOFI COMPANY

<sup>a</sup> Department of Chemical Engineering, Institute of Chemical Technology Prague, Czech Republic

<sup>b</sup> ZENTIVA k.s., U Kabelovny 130, Prague 10, Czech Republic

<sup>c</sup> Department of Chemical Engineering, Imperial College London, Great Britain

\*Frantisek.Stepanek@vscht.cz

\*s.kazarian@imperial.ac.uk

Imperial College  
London

## Aim of the study


- Enhancement of bioavailability of poorly soluble drugs
- Selection of polymers based on physico-chemical behavior
- Observation of drugs dissolution by ATR-FTIR Imaging
- Supersaturated concentration
- Crystallization

## Solid dispersion preparation

- drug dispersed in polymer matrix
- preparation by spray drying
- ratio 1:3 (drug:polymer)
- amorphous form of drug
- hollow spherical particle shape



## Introduction



### Crystallization of amorphous form to crystalline form

- local supersaturation of diffusing drug leads to precipitation of drug
- decreasing of bioavailability

### Influence of polymers to crystallization


$$B_{\text{hom}}^0 = A_{\text{hom}} \exp \left[ - \frac{16\pi r^3 \nu^2}{3k^3 T^3 (\ln S)^2} \right]$$

Supersaturation ratio  $c/c^*$       Viscosity of solution

## Materials


### Polyvinyl pyrrolidone (PVP)

- hydrophilic polymer
- soluble in water



### Soluplus

- amphiphilic polymer
- colloidal micelles in water



### Aprepitant (Drug)


- molecular weight 534.4 g/mol
- $\log P$  4.5
- $pK_a$  3.5, 9.6
- solubility in water (20 °C) 0.02 mg/ml

534.4 g/mol

4.5

3.5, 9.6

0.02 mg/ml



### Sirius T3 instrument

- Cheqsol™ <sup>1, 2</sup> method
- acid titration

## Effectiveness of polymers

### Soluplus

- increase of kinetic solubility
- prolong the duration of supersaturation


### PVP

- increase of kinetic solubility in high concentration; risk of precipitation in low

### Kinetic solubility

- concentration of Aprepitant at which precipitation is induced

## Effect of polymers to kinetic solubility of Aprepitant




## ATR-FTIR imaging recognizes crystallization in solid dispersion system


### Attenuated total reflection (ATR) - FTIR Imaging

- Bruker Equinox mid-IR imaging system in ATR mode
- Golden Gate imaging accessory fitted with a diamond ATR crystal
- 64 x 64 pixels focal array (individual pixel size 40 x 40  $\mu\text{m}$ )
- image size 635  $\mu\text{m}$  x 525  $\mu\text{m}$  (view of edge of tablet)
- spectral resolution of 8  $\text{cm}^{-1}$
- ATR imaging of dissolution has been introduced in Kazarian laboratory <sup>3, 4</sup>

### Comparison of ATR-IR spectra of crystalline and amorphous Aprepitant



### Dissolution of solid dispersion - Aprepitant:Soluplus (1:3)




### Absorbance images during dissolution

#### Effect of polymers

- Soluplus**  
slow dissolution of polymer  
gradual dissolving API  
no crystallization of API

- PVP**  
fast dissolution of polymer  
fast dissolving API  
crystallization of API  
local supersaturation

### Dissolution of solid dispersion - Aprepitant:PVP (1:3)




#### Movement of the diffusion layer in time


#### Effect of polymers

- Slow movement with constant concentration of Soluplus in core of tablet


#### Soluplus



#### Aprepitant




#### Profiles of PVP, Aprepitant and water over time



- movement of diffusion layer of all 3 components
- fast penetration of water
- low concentration of PVP and Aprepitant in 45 min
- crystallization of Aprepitant


#### Dissolution of Aprepitant:PVP



- decrease of PVP concentration (peak 1635  $\text{cm}^{-1}$ )
- decrease and following increase of Aprepitant concentration (peak 1125  $\text{cm}^{-1}$ )


#### CRYSTALLIZATION

#### Aprepitant



- shift of peak
- presence of peak

#### Crystallization of Aprepitant during dissolution



## Conclusion and future work

### Dissolution process of poorly soluble drug in solid dispersion

- Soluplus** stabilizes amorphous form by gradual slow dissolving
- PVP** does not stabilize amorphous form during dissolution
- crystallization detected by visual observation and IR spectra
- comparison of movement of diffusion layer

### Future work

- MRI study of movement of diffusion layer
- prediction of the precipitation of API depending on the concentration of polymer

<sup>1</sup> Stuart, M. and Box, K., Anal. Chem., 2005, 77(4), 983-990.

<sup>2</sup> Box, K.J., et al., J. Pharm. Sci., 2006, 95(6), 298-307.

<sup>3</sup> Kazarian S.G., Chan K. L. A., Macromolecules, 2003, 36, 9866-9872.

<sup>4</sup> Kazarian S.G., Ewing A. V., Expert Opin. Drug Deliv., 2013, 10(9), 1207-1221.

### Acknowledgment:

Financial support from the Specific University Research (MSMT 2013/2014) is gratefully acknowledged.